NEK2 and primary effusion lymphoma: To further address the feasibility and efficacy of NEK2 inhibition in PEL, we wanted to compare our findings with JH295 to another inhibitor, T-1101 tosylate, currently in phase I trials for refractory solid tumors (18, 19).